Revitalist Lifestyle Stock (OTC:RVLWF), Trade Ideas

Revitalist Lifestyle and Wellness Ltd is a mental health company engaged in the business operation of a medical clinic. The company provides ketamine-assisted psychotherapy and other novel treatments through its network of integrative mental health clinics. The company operates in three segments Clinical Operations, Research, and Corporate. It generates revenue primarily from the Clinical Operations segment.

Cannabis

Earnings

News

Penny Stocks

Psychedelics

Guidance

Financing

Offerings

Contracts

Small Cap

Legal

Management

Global

Markets

ATAI

AWKNF

CYBN

FLHLF

MASSIVE INTERACTIVE NV by Massive Interactive, Inc.

HUGE

MNMD

NUMIF

PSIL

RVLWF

Revolutionizing Psychedelics: 2 Industry Leaders Team Up On Clinical-Grade MDMA Capsules



Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies &amp; More

Events

Exclusives

At the second edition of Benzinga’s Psychedelics Capital Conference, held in sunny Miami, leaders from four major ketamine therapy companies shared their optimistic insights and guidance about the industry.

EXCLUSIVE: Ketamine Therapy Leaders Share Bold Vision For Future At Benzinga&#39;s Psychedelics Capital Conference

Ketamine clinics operator Revitalist Lifestyle &amp; Wellness Ltd. (OTCQB: RVLWF) and psilocybin bioscience and wellness platforms company Wake Network have partnered with GCM Partners LLC to offer new ketamine treatment locations in two facilities in Chicago, two in Orlando and one in Miami. 

Are You One Of The Lucky 50,000? New Pact Opens Psychedelic Treatment Floodgates

REVITALIST LIFESTYLE WLNS by Revitalist Lifestyle and Wellness Ltd.

Revitalist Lifestyle and Wellness Ltd

SIEB

Siebert Receives Nasdaq Deficiency Notification For Delayed Filing Of Annual Report On Form 10-K

<ul>
<li>Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 million in clinical development and CMC costs over the next three years and an additional approximately $61 million in forecasted obligations through the patent life of rezafungin</li>
<li>Cidara to further focus on advancing Cloudbreak development programs, including a planned IND filing for its lead oncology candidate, CBO421, as well as advancing other pipeline assets &nbsp;</li>
</ul>
SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>), a biotechnology company using its proprietary Cloudbreak&#xAE;&nbsp;platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that it has entered into an asset purchase agreement with its current partner, Mundipharma&#x2A;, for the divestiture of rezafungin. Mundipharma currently has commercial rights to rezafungin outside the U.S. and Japan. Mundipharma purchased the assets in consideration of its assumption of the ongoing obligation to conduct and fund the ReSPECT Phase 3 clinical trial, the costs of the rezafungin patent portfolio and CMC and regulatory obligations. Cidara estimates that it will achieve approximately $128 million in cost savings over the patent life of rezafungin comprised of approximately $67 million in clinical development expense, including the cost of the potential upsizing of the ReSPECT trial and CMC costs over the next three years, and an additional approximately $61 million in forecasted obligations through the expected patent life of rezafungin.
"We are proud to have advanced rezafungin from preclinical development to approval in the US, EU, and UK for the treatment of patients suffering from life-threatening fungal infections," said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. "With that accomplished, we believe the substantial cost savings enabled by this transaction will enable us to deploy our capabilities to progress our promising Cloudbreak pipeline and create opportunities to advance potentially transformational new therapies in oncology and other disease areas."
Under the terms of the asset purchase agreement, all future royalties and milestones from Mundipharma and Melinta Therapeutics that were previously payable to Cidara, will transfer to Mundipharma. The purchased assets also include all rezafungin intellectual property rights, product data, regulatory approvals, rezafungin product and comparator inventory, specified prepaid assets and specified contracts. Prior to the sale, Mundipharma paid Cidara the $2.786 million milestone that became payable for the approval of rezafungin acetate for the treatment of invasive candidiasis in adults by the United Kingdom Medicines and Healthcare products Regulatory Agency. Mundipharma also agreed to waive Cidara's obligation to reimburse Mundipharma for a $11.145 million milestone advance if Cidara completes transition services and the transfer of assets in accordance with the definitive agreements.
&#x2A;Assets and rights acquired by Napp Pharmaceutical Group Limited, a member of the international network of Mundipharma independent associated companies.

Asset Sales

CDTX

Cidara Therapeutics Announces Divestiture Of Rezafungin To Mundipharma To Focus On Advancing The Clinical Development Of Cloudbreak DFC Pipeline; Transaction Provides Company With An Estimated ~$128M In Cost Savings

First American Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FAF#NYSE">FAF</a>) reported quarterly earnings of $0.45 per share which missed the analyst consensus estimate of $0.59 by 23.73 percent. This is a 21.05 percent decrease over earnings of $0.57 per share from the same period last year. The company reported quarterly sales of $1.425 billion which missed the analyst consensus estimate of $1.430 billion by 0.32 percent. This is a 1.45 percent decrease over sales of $1.446 billion the same period last year.

Earnings Misses

First American Financial Q1 2024 Adj EPS $0.45 Misses $0.59 Estimate, Sales $1.425B Miss $1.430B Estimate

ServiceNow, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) reported its first-quarter financial results after the bell Wednesday. Here's a <a href="https://www.benzinga.com/pressreleases/24/04/b38415464/servicenow-reports-first-quarter-2024-financial-results">look at the highlights</a>.
The Details:
ServiceNow reported quarterly earnings of $3.41 per share which beat the analyst consensus estimate of $3.14 by 8.6%. 
Quarterly sales came in at $2.6 billion which beat the analyst consensus estimate of $2.59 billion and represents a 24.19% increase over sales of $2.1 billion from the same period last year.
The company reported subscription revenues of $2.523 billion in the first quarter, representing 25% year-over-year growth, 24.5% in constant currency. ServiceNow highlighted recording eight transactions over $5 million in net new ACV in the first quarter, up 100% year-over-year. 
&#8220;ServiceNow is off to a fast start with an outstanding first quarter,&#8221; said ServiceNow CEO Bill McDermott. &#8220;As leaders seek significant productivity improvements, ServiceNow has first mover advantage with years of investment in AI technology and talent. Our GenAI offerings are the fastest selling in the company&#8217;s history. We are humbled by the trust our customers are investing in our platform. As we engineer Now Assist AI into every business workflow across every enterprise, we are giving people the power to know more, care more, and do more.&#8221;
Outlook:&nbsp;
ServiceNow sees second-quarter adjusted subscription revenue growth of 22%. 
The company initiated a program to hedge a portion of its forecasted foreign currency denominated revenues. While the cash flow hedging program is designed to reduce the impact of foreign currency exchange rate fluctuations on its subscription revenues, the strengthening of the U.S. Dollar since December 31, 2023 has still resulted in an adverse impact to its 2024 guidance. 
The company expects negative 2-point impact to its second-quarter cRPO growth, as the balance of its U.S. Federal business contracts containing 12-month renewal terms amortized into revenue.
Related News: <a href="https://www.benzinga.com/news/24/04/38407505/whats-going-on-with-advanced-micro-devices-stock">What&#8217;s Going On With Advanced Micro Devices Stock?</a>
NOW Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, ServiceNow shares are down 4.91% after-hours at $709.75 at the time of publication Tuesday.
Image: Shutterstock

Movers

ServiceNow Reports Q1 Results and Q2 Guidance, Shares Fall

RTX's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) short percent of float has fallen 14.43% since its last report. The company recently reported that it has 34.63 million shares sold short, which is 2.61% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.8 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>RTX Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713991521_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for RTX has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing RTX's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, RTX's peer group average for short interest as a percentage of float is 2.39%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into RTX's Recent Short Interest

Hertz Global Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NYSE">HTZ</a>) short percent of float has risen 3.56% since its last report. The company recently reported that it has 25.52 million shares sold short, which is 20.96% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.83 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Hertz Global Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713991516_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Hertz Global Holdings has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Hertz Global Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Hertz Global Holdings's peer group average for short interest as a percentage of float is 6.79%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(HTZ) - Analyzing Hertz Global Holdings's Short Interest

W&amp;T Offshore's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTI#NYSE">WTI</a>) short percent of float has fallen 16.2% since its last report. The company recently reported that it has 19.54 million shares sold short, which is 19.97% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.56 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>W&amp;T Offshore Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713991511_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for W&amp;T Offshore has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing W&amp;T Offshore's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, W&amp;T Offshore's peer group average for short interest as a percentage of float is 3.46%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(WTI) - Analyzing W&T Offshore's Short Interest

MaxLinear Sees Q2 2024 Revenue $90M-$110M Vs $105.252M Est.

Biotech

General

ACRV

Acrivon Therapeutics Reports A 50% Confirmed Overall Response Rate Observed With ACR-368 In Oncosignature-Positive Gynecological Cancers; Initial Clinical Validation Of AP3 Patient Selection Platform, Demonstrated Ability To Prospectively Predict ACR-368 RECIST Responders

•&nbsp; Initial ACR-368 Phase 2b clinical data in patients with ovarian or endometrial cancers (n=26; 10 OncoSignature-positive and 16 OncoSignature-negative) are being presented •&nbsp;&nbsp;A 50% confirmed overall response rate observed with ACR-368 in OncoSignature-positive gynecological (ovarian and endometrial) cancers •&nbsp;&nbsp;Initial clinical validation of AP3 patient selection platform, demonstrated ability to prospectively predict ACR-368 RECIST responders (p-value = 0.0038) •&nbsp;&nbsp;ACR-2316, a potential first-in-class dual WEE1/PKMYT1 inhibitor, IND timeline accelerated with filing now expected in Q3 2024 •&nbsp;&nbsp;Acrivon hosts Corporate R&amp;D event webcast today at 4:15 pm ET
WATERTOWN, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRV#NASDAQ">ACRV</a>), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), to host a corporate R&amp;D event. The company plans to present initial positive clinical data from the ongoing registrational-intent Phase 2 ACR-368 clinical trials, which showed prospective validation of the proprietary ACR-368 OncoSignature patient selection biomarker test with a 50% confirmed objective response rate (ORR) in patients with ovarian and endometrial cancers. Acrivon is also sharing new preclinical data for ACR-2316, now with accelerated IND filing timelines, as well as actionable findings with the machine learning-enabled AP3 platform.
"Today we present initial clinical data from our ongoing Phase 2 clinical trial which we believe highlights the power of our next generation proteomics-based AP3 precision medicine platform," said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics. "For the first time, we share statistically significant prospective validation of our AP3 patient selection approach via our ACR-368 OncoSignature assay, which demonstrated the ability to effectively identify cancer patients whose tumors are likely to respond to ACR-368 monotherapy treatment. We are extremely gratified to not only confirm the ability to identify and enrich for patient responders with ovarian cancer, but also for patients with endometrial cancer, a new tumor type identified and predicted to be sensitive to ACR-368 by our AP3 platform prior to clinical trial initiation."
"Today's R&amp;D event provides us an opportunity to present the compelling preclinical data of our AP3-based, rationally-designed ACR-2316 dual WEE1/PKMYT1 inhibitor," said Kristina Masson, Ph.D., M.B.A., co-founder and executive vice president of business operations at Acrivon Therapeutics, Inc. and president and CEO of the company´s research subsidiary Acrivon AB. "We are excited to announce our accelerated timelines for IND filing, now expected in the third quarter with potential clinical study initiation now anticipated in the fourth quarter of this year. We believe this potential first-in-class asset, which is specifically designed for superior single-agent activity as demonstrated in preclinical studies against benchmark inhibitors, has the potential to address significant unmet treatment needs against a broad range of tumors in patients with limited treatment options."
Company Provides Program and Data Highlights:
<ul>
<li>An overview of the broad, actionable scientific capabilities and clinically demonstrated deliverables of the AP3 platform</li>
<li>Initial ACR-368 clinical data in patients with ovarian or endometrial cancers (n=26; 10 OncoSignature-positive and 16 OncoSignature-negative) in the ongoing registrational-intent Phase 2b trial are being presented (data cut as of April 1, 2024).
<ul>
<li>A confirmed ORR (per RECIST 1.1) of 50% was observed in the prospective cohort of OncoSignature-positive patients who were efficacy-evaluable. All confirmed responders continue to be on treatment, median duration of response (DoR) has not yet been reached. Notably, endometrial cancer is a new tumor type with significant unmet medical need that was identified and predicted to be sensitive to ACR-368 by AP3 indication screening.</li>
<li>Initial, prospective validation of the AP3-based ACR-368 OncoSignature assay demonstrating its ability to identify ovarian and endometrial patients sensitive to ACR-368 monotherapy in the ongoing clinical trial, with clear segregation of RECIST responders in the OncoSignature-positive (50% confirmed ORR in 10 patients) versus OncoSignature-negative (0% ORR in 16 patients) arms (p-value=0.0038).</li>
<li>In the OncoSignature-negative arm with ovarian or endometrial cancers, encouraging signs of clinical activity were observed in response to ACR-368 with ultra-low dose gemcitabine at the recommended Phase 2 combination dose, with 8 out of 16 patients achieving stable disease.</li>
<li>Consistent with past trials, the ACR-368 treatment-related adverse event profile was predominantly reversible and transient with only mechanism-based, hematological adverse events.</li>
</ul>
</li>
<li>ACR-2316, a potential first-in-class, potent WEE1/PKMYT1 inhibitor continues to advance rapidly with IND filing now expected in Q3 2024 (vs. previous guidance of Q4 2024) and the initiation of a clinical trial is anticipated in Q4 2024. ACR-2316 is uniquely designed by AP3 for superior single-agent activity and to overcome limitations of current WEE1 inhibitors and PKMYT1 inhibitors.</li>
<li>A preview of the AP3 Interactome, which is a proprietary, machine-learning-enabled interactive platform used to uncover actionable drug-induced pathway effects across all studies.</li>
</ul>
A live and recorded webcast of the event will be available through a link on the Events &amp; Presentations page within the investor section of the company's website at <a href="https://www.globenewswire.com/Tracker?data=rSHAfaV-oyIgthRiyndv7eC-M1ISwhUkw17noYmbQt_aDTK9Z6tbbEmPFQPcT4m5VKc5KNO5CvpkByREn57i6Xvf5wWx-nkBxYvaVU0V-BcKIx4zeLvlGzrzKcbufXN0y-w4Vj3Ifj2T5Md5tz9fapO5vq2PlOANjTAJa6ZOGYRFEJ2NMvQ9rc-zJE-PV8CZ">https://ir.acrivon.com/news-events/events-presentations</a>. The webcast will be available for at least 30 days following the event.

Acrivon Therapeutics Reports Initial Positive Clinical Data For ACR-368 And Pipeline Program Progress Today At Corporate R&D Event

Gracco Reaffirms FY Revenue Guidance Of Low Single-Digit Growth On Organic, Constant Currency Basis.

Assumptions underlying the annual earnings&nbsp;guidance&nbsp;as provided in our press release issued on February 20, 2024 are unchanged.

Community Health Systems Reaffirms Annual Earnings Guidance For 2024

Chipotle Mexican Grill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) reported financial results for the first quarter Wednesday after the bell. Here&#8217;s a rundown of the report and a look at why <a href="https://www.benzinga.com/pressreleases/24/04/n38415509/chipotle-announces-first-quarter-2024-results">shares are sizzling after hours</a>.
Q1 Earnings: Chipotle said first-quarter revenue increased 14.1% year-over-year to $2.702 billion, which beat the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a>&nbsp;of $2.675 billion, according to&nbsp;<a href="https://benzinga.grsm.io/gxjhpowx7zks" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.&nbsp;The fast-casual restaurant chain company reported adjusted earnings of $13.37 per share, which beat analyst estimates of $11.68 per share.&nbsp;
Comparable restaurant sales increased 7% year-over-year due to higher transactions and a&nbsp;1.6%&nbsp;increase in average check. Digital sales represented 36.5% of food and beverage revenue. Operating margin was 16.3% in the first quarter, up from 15.5% year-over-year.&nbsp;
Chipotle said it opened 47 new restaurants in the quarter, and 43 of those locations included a Chipotlane. The company also repurchased $25 million of its stock during the first quarter and has $399.1 million remaining under its share repurchase authorization. 
&#8220;We had another outstanding quarter driven by our improvement in throughput and successful marketing initiatives, including Braised Beef&nbsp;Barbacoa and Chicken Al Pastor, which drove strong sales and transactions,&#8221; said&nbsp;Brian Niccol, chairman and CEO of Chipotle.
&#8220;The results we are seeing from our focus on developing exceptional people, preparing delicious food and fast throughput gives me confidence that we can achieve our long-term target of more than doubling our business in&nbsp;North America&nbsp;and expanding internationally.&#8221; 
Outlook: Chipotle expects full-year 2024 comparable restaurant sales growth in the mid- to high-single-digit range. The company anticipates opening between 285 and 315 new restaurants in 2024 with over 80% including a Chipotlane.
Chipotle shares appear to be responding favorably to the company&#8217;s better-than-expected results paired with an upbeat forecast for continued comparable sales growth. Chipotle&#8217;s first-quarter earnings call is scheduled for 4:30 p.m. ET.
Don&#8217;t Miss: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38412499/treasury-yields-rise-tesla-jumps-on-cheaper-model-pledge-yen-plummets-to-34-year-lows-what">Treasury Yields Rise, Tesla Jumps On Cheaper Model Pledge, Yen Plummets To 34-Year Lows: What&#8217;s Driving Markets Wednesday?</a>
CMG Price Action:&nbsp;<a href="https://www.benzinga.com/quote/CMG" target="_blank" rel="noreferrer noopener">Chipotle shares</a>&nbsp;were up 3.30% after hours at $3,023.29 at the time of publication Wednesday, according to&nbsp;<a href="https://benzinga.grsm.io/gxjhpowx7zks" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Courtesy of Chipotle.

Restaurants

After-Hours Center

Chipotle Mexican Grill Q1 Earnings: Revenue Beat, EPS Beat, Comparable Sales Up 7% And More

WLDS

Wearable Devices Granted 180-Day Extension By Nasdaq To Regain Compliance With Minimum Bid Requirement

Invited to Present Updated Endometrial Cancer Data During Special Session "ASCO Plenary Series: Rapid Abstract Updates"
NEWTON, Mass., April 24, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several abstracts detailing new selinexor data have been selected for presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024&nbsp;ASCO Annual Meeting) being held May 31 - June 4 in Chicago, IL. The Company is pleased to have received an invitation to present updated Endometrial Cancer data during a special session called "ASCO Plenary Series: Rapid Abstract Updates."
A highlight at the 2024 ASCO Annual Meeting includes a rapid oral abstract update of long-term follow-up of selinexor maintenance in patients with TP53wt advanced or recurrent endometrial cancer – a pre-specified subgroup analysis from the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study.
"As we follow the endometrial cancer patients whose tumors are TP53wt and evaluate the long-term benefit, our confidence for selinexor to provide meaningful benefit for patients continues to grow," said Reshma Rangwala, MD, PhD, Chief Medical Officer of Karyopharm. "We are excited about the advancement of our three, phase three programs in areas of high unmet need in endometrial cancer, myelofibrosis, and multiple myeloma."
Details for the 2024 ASCO Annual Meeting abstracts are as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Abstract Title</td>
<td colspan="1" rowspan="1">Presentation Type</td>
<td colspan="1" rowspan="1">Abstract #</td>
<td colspan="1" rowspan="1">Session Date/Time</td>
</tr>
<tr>
<td colspan="4" rowspan="1">Endometrial Cancer</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Updates on Abstract 427956: Long-Term Follow up of Selinexor Maintenance in Patients with TP53wt Advanced or Recurrent Endometrial Cancer—A Pre- Specified Subgroup Analysis from the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study (Rapid abstract update presentation following July 25, 2023 Plenary Series)</td>
<td colspan="1" rowspan="1">Rapid Oral</td>
<td colspan="1" rowspan="1">427956</td>
<td colspan="1" rowspan="1">
June 1, 2024 &nbsp;
12:30pm-1:30pm CDT
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Phase 3 Dose Selection for Selinexor in TP53wt Endometrial Cancer Based on Exposure-Response Analysis</td>
<td colspan="1" rowspan="1">Poster</td>
<td colspan="1" rowspan="1">5594</td>
<td colspan="1" rowspan="1">
June 3, 2024 &nbsp;
9:00am – 12:00pm CDT
</td>
</tr>
<tr>
<td colspan="4" rowspan="1">Myelofibrosis</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Phase 3 Trial Design: Randomized Double-Blind Study Evaluating Selinexor, an XPO1 inhibitor, Plus Ruxolitinib in Jaki- Naïve Myelofibrosis</td>
<td colspan="1" rowspan="1">Poster</td>
<td colspan="1" rowspan="1">TPS6594</td>
<td colspan="1" rowspan="1">
June 3, 2024 &nbsp;
9:00am – 12:00pm CDT
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Phase 2 Study Trial Design: Evaluating Selinexor Monotherapy in Patients with Jaki-Naïve Myelofibrosis and Moderate Thrombocytopenia</td>
<td colspan="1" rowspan="1">Poster</td>
<td colspan="1" rowspan="1">TPS6593</td>
<td colspan="1" rowspan="1">
June 3, 2024 &nbsp;
9:00am – 12:00pm CDT
</td>
</tr>
</tbody>
</table>
</figure>
About XPOVIO&#xAE; (selinexor) XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds to be approved for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved in the U.S. and marketed by Karyopharm in multiple oncology indications, including: (i) in combination with Velcade&#xAE; (bortezomib) and dexamethasone (XVd) in patients with multiple myeloma after at least one prior therapy; (ii) in combination with dexamethasone in patients with heavily pre-treated multiple myeloma; and (iii) in patients with diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. XPOVIO (also known as NEXPOVIO&#xAE; in certain countries) has received regulatory approvals in a growing number of ex-U.S. territories and countries, including&nbsp;Europe, the&nbsp;United Kingdom,&nbsp;South Korea,&nbsp;Israel,&nbsp;Singapore,&nbsp;Hong Kong, Mainland China,&nbsp;Australia,&nbsp;Canada,&nbsp;Taiwan&nbsp;and&nbsp;Macau&nbsp;and is marketed in those areas by Karyopharm's global partners. Selinexor is also being investigated in several other mid- and late-stage clinical trials across multiple high unmet need cancer indications, including in endometrial cancer and myelofibrosis.

KPTI

Karyopharm Announces Presentations In Endometrial Cancer And Myelofibrosis At The 2024 American Society Of Clinical Oncology Annual Meeting

CNMD

CONMED Sees FY24 Adj. EPS $4.25-$4.35 Vs $4.33 Est.; Revenue $1.330B-$1.355B Vs $1.350B Est.

Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) reported first-quarter financial results <a href="https://www.benzinga.com/calendars/earnings">after the market close Wednesday.</a>
Here are the key highlights.
What Happened: Ford reported first-quarter revenue of $42.8 billion, which was up 1.3% year-over-year. The revenue total beat a Street consensus estimate of $40.1 billion, according to<a href="https://www.benzinga.com/pro/feature/newsfeed?gspk=bHVrZWphY29iaTUzNDg&amp;gsxid=tdEE0VrK8Jeg&amp;ref=lukejacobi5348"> data from Benzinga Pro</a>.
The company reported earnings per share of 49 cents in the first quarter, which beat a Street estimate of 42 cents per share.
Revenue by segment for the first quarter was:
Ford Blue: $21.8 billion, -13% year-over-year
Ford Model e: $0.1 billion, -84% year-over-year
Ford Pro: $18.0 billion, +36% year-over-year
Wholesale units by segment were as follows:
Ford Blue: 626,000, -11% year-over-year
Ford Model e: 10,000, -20% year-over-year
Ford Pro: 409,000, +21% year-over-year
The company's Ford Pro unit saw strong growth led by high demand for Super Duty work trucks, Transit vans and software, the company said. The EBIT of the segment was up more than double.
The Model e division, which houses electric vehicles, was affected by industrywide pricing pressure on EVs and posted an EBIT loss of $1.3 billion in the first quarter. Ford said it expects the Model e unit&#8217;s costs to improve going forward, but for the segment to face top-line pressure on sales.
"Customers want vehicles that they're passionate about, choices in how they're powered, quality that's constantly getting better and great value," Ford CEO Jim Farley said. 
"With Ford+, we're increasingly giving them all those things in ways that others don't and creating a company that will lead for the long haul."
Related Link: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38380272/ford-enjoys-bullish-momentum-but-faces-buying-pressure-ahead-of-q1-earnings">Ford Enjoys Bullish Momentum, Faces Buying Pressure Ahead Of Q1 Earnings</a>
What's Next: Ford is guiding for full-year adjusted earnings before interest and taxes to come in a range of $10 billion to $12 billion, unchanged from its previously announced guidance. The company said EBIT are tracking toward the higher end.
Ford&#8217;s guidance calls for adjusted free cash flow of between $6.5 billion and $7.5 billion for the full fiscal year, up from a previously announced range of $6 billion to $7 billion.
The company sees capital expenditures coming in a range of $8 billion to $9 billion for the full year, slightly improved from a prior range of $8 billion to $9.5 billion.
F Price Action: Ford shares are up 2.93% to $13.33 in after-hours trading Wednesday versus a 52-week trading range of $9.63 to $15.42.
Read Next: <a href="https://www.benzinga.com/news/24/04/38285214/fords-mustang-gallops-into-60th-year-still-a-pony-with-plenty-of-kick">Ford&#8217;s Mustang Gallops Into 60th Year: Still A Pony With Plenty Of Kick</a>
Photo courtesy of Ford.

Equities

Ford Q1 Earnings Highlights: Automaker Beats Street Estimates, Guidance Improves, EV Revenue Falls 84%

Kronos Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRON#NASDAQ">KRON</a>), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present a study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors from the ongoing Phase 1/2 trial, KB-0742-1001 (<a href="https://www.globenewswire.com/Tracker?data=QjH0e_MRq1WquJkxdHYjSAZIfnvGOasHqZswK9OfOcGY0UH83vAQfyaV3FypSmcxIINZCYMZXpa4XArWukfeghvgg8oFwMYtc06ED7zOgMw59gW6ANyeKC_67qe-OywG5Uasdhoi49nvxZgPR1Tlsw==">NCT04718675</a>), at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held from May 31 – June 4, 2024 in Chicago, Illinois and online. &nbsp;
"We are looking forward to sharing updated data from KB-0742-1001, our ongoing Phase 1/2 trial of KB-0742, including data from the 80mg three days on/four days off dosing regimen. The trial is designed to assess the safety, tolerability, and preliminary efficacy at increasing dose levels of KB-0742, an orally bioavailable and selective CDK9 inhibitor with a long half-life," said Norbert Bischofberger, Ph.D., chief executive officer and president of Kronos Bio. "Our last update at the 2023 AACR-NCI-EORTC meeting showed that KB-0742 exhibited anti-tumor activity while maintaining an acceptable safety profile at the 60mg three-days-on, four-days-off dose, which is an important step as we seek to identify the optimal dose of KB-0742."
Details for the ASCO 2024 abstract are as follows:
Title: Study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors Presenter: Brian A. Van Tine, M.D., Ph.D., Washington University in St. Louis Abstract ID#: 3102 Poster Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Location: Hall A, McCormick Place, Chicago, Illinois Poster Board #: 247 Date and Time: Saturday, June 1, 2024, from 9:00 a.m. to 12:00 p.m. CDT

KRON

Kronos Bio To Present Clinical Update On Phase 1/2 Trial Of KB-0742 At The 2024 ASCO Annual Meeting

PLXS

Plexus Continues To Anticipate Strong Finish To FY24 With Expansion In Revenue And Non-GAAP Operating Margin Each Quarter

Meritage Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTH#NYSE">MTH</a>) reported quarterly earnings of $5.06 per share which beat the analyst consensus estimate of $3.55 by 42.54 percent. The company reported quarterly sales of $1.468 billion which beat the analyst consensus estimate of $1.288 billion by 14.01 percent. This is a 14.78 percent increase over sales of $1.279 billion the same period last year.